In this community, professionals share information regarding the clinical, programmatic and community-oriented aspects of early diagnosis, treatment and prevention of multi-drug-resistant tuberculosis (MDR-TB). Members also use this forum to promote universal access to quality care for MDR-TB.

Community moderators

Masoud Dara, MD
WHO Europe - EURO
Christopher Gilpin, PhD, MPH
World Health Organization - WHO
Dylan Tierney
Brigham and Women's Hospital, Division of Global Health Equity

Recent community activity

TB diagnosis in India: how a diagnosis is delayed

Ariful Basher replied

I am not totally agree with the findings . One problem is our patient knowledge and treatment seeking behaviour. I have seen many patients had taken antibiotics days after days from public hospital out door services. Our problem is our policy . In Bangladesh any antibiotics can sell by pharmacist ... read more

Updated: 23 Jul, 2016
Replies: 10

Case Study: Catalyzing the market for accurate tuberculosis testing in India's extensive private sector through IPAQT

Madhukar Pai, MD, PhD replied

Thanks, Erica. Yes, the private sector is a major source of health care in 12 of the 22 countries with the highest TB burden, including India, Pakistan, the Philippines, Bangladesh, Afghanistan, Kenya, Uganda, Vietnam, Indonesia, Myanmar, Nigeria and Cambodia. In these economies, even poor patients with TB seek care from ... read more

Updated: 21 Jul, 2016
Replies: 3

Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?

by Madhukar Pai, MD, PhD

Please see this attached new, open access paper in ERJ: http://erj.ersjournals.com/content/early/2016/07/13/13993003.00543-2016?ctkey=shareline Abstract The global roll-out of Xpert MTB/RIF (Cepheid Inc., Sunnyvale, CA, USA) has changed the diagnostic landscape of tuberculosis (TB). More than 16 million tests have been performed in 122 countries since 2011, and detection of multidrug-resistant TB has ... read more

Updated: 14 Jul, 2016
Replies: 0

Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project

Zea Rahim replied

Dear Kunjan, Greetings from Bangladesh! It may be associated with MDR strains. Please do culture and test the sensitivity of isolate. Regards Dr. Md. Zeaur Rahim Zeaur Rahim M. Phil, DRSU, Ph.D Mycobacteriology Laboratory International Centre for Diarrhoeal Disease Research, Bangladesh GPO Box 128, Dhaka 1000, Bangladesh Telephone: 880 2 ... read more

Updated: 14 Jul, 2016
Replies: 6

New community members

User Photo

Pukar Ghimire

Affiliated Organizations

tribhuvan university teaching hospital, Institute of medicine

Work Locations

Nepal

User Photo

Mercy Raymond

Affiliated Organizations

Hospital

Work Locations

Nigeria

User Photo

Jennifer Sullivan

Affiliated Organizations

MASS Design Group

Work Locations

United States